Physician profile
Hadyn Gause
NPI 1376031393
$2,026.23
in general payments reported to CMS, 2019-2025
27 companies · $862 in 2025
The $862 reported for 2025 was more than what 84% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $316 · 2023: $520 · 2024: $328 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $276.66 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $267.05 | 2023-2025 | |
| Novo Nordisk INC | $222.32 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $192.63 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $169.44 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.96 | 2022-2025 | Xifaxan, Trulance |
| Amgen INC. | $81.07 | 2023-2025 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.73 | 2022-2025 | Jardiance |
| Pfizer INC. | $61.54 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.13 | 2022 | |
| Daiichi Sankyo INC. | $59.04 | 2023-2024 | Injectafer |
| Xeris Pharmaceuticals, INC. | $56.86 | 2022-2023 | Gvoke Hypopen |
| Astellas Pharma US INC | $53.21 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $49.66 | 2025 | Gemtesa |
| Abbott Laboratories | $42.71 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $37.09 | 2025 | |
| Novartis Pharmaceuticals Corporation | $30.70 | 2023 | |
| Edwards Lifesciences Corporation | $28.72 | 2025 | Sapien 3 Ultra Resilia |
| Corcept Therapeutics | $26.91 | 2024 | Korlym |
| Janssen Pharmaceuticals, INC | $26.16 | 2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $23.14 | 2022 | |
| Ironwood Pharmaceuticals, INC | $18.54 | 2022 | |
| Merck Sharp & Dohme LLC | $17.95 | 2025 | Gardasil 9, Capvaxive |
| Insulet Corporation | $16.75 | 2025 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $15.04 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.75 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hadyn Gause listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.